PUMA BIOTECHNOLOGY, INC. (PBYI)

9.06 -1.95% (-0.18)

Over 1Y: +82.3%

2026-08-28
Style
Area Line Line with markers Steps Candlesneeds a shorter window Hollow candlesneeds a shorter window Barsneeds a shorter window

Candles need the day’s open, high and low. Those are being collected now — a company shows them once its history has been refreshed.

4 6 8
Aug Oct Dec Feb Apr Jun Aug

Financials Quarterly

Figures
Revenue Gross Profit Operating Income Cost of Revenue Operating Cash Flow Free Cash Flow Net Income

A share count and earnings a share are not here: neither is money, so neither can share this axis. Both have their own panel on All charts.

All charts ›
Q3 '25 — Revenue: 54.5M Q3 '25 — Operating Cash Flow: 9.7M Q3 '25 — Free Cash Flow: 9.7M Q3 '25 — Net Income: 8.8M Q4 '25 — Revenue: 75.5M Q4 '25 — Operating Cash Flow: 14.4M Q4 '25 — Net Income: 13.4M Q1 '26 — Revenue: 44.8M Q1 '26 — Operating Cash Flow: 15.4M Q1 '26 — Free Cash Flow: 15.4M Q1 '26 — Net Income: -3.8M Q2 '26 — Revenue: 56.5M Q2 '26 — Operating Cash Flow: 1.6M Q2 '26 — Free Cash Flow: 1.6M Q2 '26 — Net Income: 8.2M 0 20M 40M 60M 80M
Q3 '25 Q4 '25 Q1 '26 Q2 '26
Revenue Gross Profit Operating Cash Flow Free Cash Flow Net Income

Figures as at 2026-06-30, reported in USD. The newest fact in the filings is dated 2026-06-30, 61 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Quality

How much of the revenue is really kept — and what did it take to earn it?

5.8
ROIC 42.9%
OE margin 14.7%
Oper. margin 13.2%
Accruals -7.5%
Capex / sales 0.031%
Gross margin 74.8%
ROA 13.9%
ROCE 21.3%
FCF margin 17.8%
ROE 19.3%
OCF / EBIT 1.4×
OCF margin 17.8%

5 of 17 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Valuation

What does the price ask for what the company earns, owns and pays out?

0.5
Div. yield —
EV/EBIT —
EV/GP —
EV/OE —
EV/Sales —
FCF yield —
Fwd P/E —
P/B —
P/C —
P/E —
PEG —

0 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Durability

How predictable is the revenue, and how much of it is already committed?

3.4
RPO / sales —
RPO growth —
Segment HHI —

3 of 7 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Resilience

Can the balance sheet absorb a bad year?

7.6
ND/EBITDA —
Cash / Debt 8.3×
Debt / Eq 0.082×
Debt payback 0.0 yr
Payout 0.0%
Quick ratio 2.6×
F-score 7.0 pts
Cash runway —

3 of 12 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

Growth

Is the business getting bigger, and is it getting more profitable?

2.1
Sales/sh Y/Y -5.8%
EBIT CAGR +7.4%
Sales Q/Q +7.8%
EBIT Y/Y -33.9%
EPS Y/Y -46.5%
Div. growth —
EPS CAGR 4Y —
EPS next Y —

4 of 13 counted in the score. The rest are measures this model does not include here, or figures these filings do not carry — switch any of them on and the score changes.

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.